INN – Dornase alfa
Genetically engineered variant of the natural human enzyme that breaks down extracellular DNA.
Indications: symptomatic therapy in combination with standard therapy of cystic fibrosis in patients with the value of Forced Vital Capacity (FVC) at least 40% of the norm to improve lung function.
Dornase alpha is a basic mucolytic drug for the treatment of cystic fibrosis.
- Rapid and significant reduction of sputum viscosity
- Significant improvement in respiratory function
- Reducing the risk of upper respiratory infection
Generium is the first company in the world to develop and produce dornase alpha biosimilar.